Preoperative Systemic Immune-Inflammatory Index as a Predictive Biomarker for Lower Extremity Deep Vein Thrombosis after Breast Cancer Surgery: Stratified Nursing Intervention to Reduce Incidence

17 December 2023: Clinical Research

Lu Tian ^12345ABCDEF* , Jun Zhu ^5ABDF , Xia Li ^5ACD , Lei Huang ^2346ACDEFG* , Li Tian ^12347ACDEFG

DOI: 10.12659/MSM.942087

Med Sci Monit 2023; 29:e942087

Table 3 Univariate analysis of surgical data between the LEDVT and non-LEDVT groups.

Items	Non-LEDVT (n =506)	LEDVT (n=46)	χ2	P
Surgical type, n (%)
Radical mastectomy	328 (64.8)	33 (71.7)	0.892	0.345
Breast conserving surgery	6 (1.2)	0 (0)	0.551	1.000
Radical mastectomy+LN biopsy	152 (30.0)	11 (23.9)	0.761	0.383
Breast conserving+LN biopsy	20 (4.0)	2 (4.3)	0.017	0.704
The left side of the tumor, n (%)	244 (48.2)	21 (45.7)	0.112	0.738
LN involvement, n (%)	150 (29.6)	20 (43.5)	3.786	0.066
Pathology type, n (%)
Invasive ductal	420 (83.0)	36 (78.3)	0.660	0.416
Ductal/in situ	30 (5.9)	5 (10.9)	1.733	0.200
Mucinous	13 (2.6)	0 (0)	1.210	0.604
Mixed	10 (2.0)	3 (6.5)	3.789	0.086
Others	33 (6.5)	2 (4.4)	0.336	0.758
T Stage			8.147	0.043
T0/Tis/Tx	86 (17.0)	11 (23.9)
T1	198 (39.1)	21 (45.7)
T2	204 (40.3)	10 (21.7)
T3	18 (3.6)	4 (8.7)
N Stage			23.847
N0	356 (70.4)	24 (52.2)
N1	108 (21.3)	8 (17.4)
N2	13 (2.6)	3 (6.5)
N3	29 (5.7)	11 (23.9)
Pathology features, n (%)
Luminal A	31 (6.1)	5 (10.9)	1.556	0.210
Luminal B, HER-2−	220 (43.5)	16 (34.8)	1.303	0.254
Luminal B, HER-2+	145 (28.7)	10 (21.7)	0.999	0.318
HER-2 overexpression	79 (15.7)	10 (21.7)	1.170	0.279
Triple negative	31 (6.1)	5 (10.9)	1.556	0.210
Postoperative chemotherapy, n (%)	218 (43.1)	13 (28.3)	3.807	0.061
The time of postoperative DVT (day)	–	3 (2,4)		–
^* Other types include invasive lobular carcinoma, invasive micropapillary carcinoma, Paget’s disease of the breast, etcL. DVT – deep vein thrombosis; HER-2 – human epidermal growth factor receptor-2; LN – lymph node; LEDVT – deep vein thrombosis of lower extremity.